D-1546-2022 Class III Terminated
FDA drug recall D-1546-2022 was initiated by Leading Pharma, LLC on Aug 23, 2022 and is designated Class III. Reason for recall: Superpotent Drug: Assay value found to be 110.6% in Chlomipramine Hydrocholoride capsules The recall status is terminated (terminated Sep 28, 2023). Affected quantity: 960 bottles (100 capsules).
Recall details
- Product Type
- Drugs
- Report Date
- Oct 5, 2022
- Initiation Date
- Aug 23, 2022
- Termination Date
- Sep 28, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 960 bottles (100 capsules)
Product description
ClomiPRAMINE Hydrochloride Capsules, USP 25mg, 100-count bottles, Rx only, LEADING PHARMA, Manufactured by: Leading Pharma, LLC, Fairfield, NJ 07004, NDC 69315-167-01
Reason for recall
Superpotent Drug: Assay value found to be 110.6% in Chlomipramine Hydrocholoride capsules
Distribution pattern
Nationwide within the United States
Code information
Lot#: B14221, Exp. Date 02/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1546-2022
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026